INTRODUCTION {#s1}
============

CBF-AML, including AML with t(8;21) and AML with inv(16)/t(16;16), accounts for approximately 25% of pediatric and 15% of adult *de novo* AML patients. Compared to other AML subsets, CBF-AML is considered to have a good prognosis. Both alterations result in disruption of genes encoding subunits of the CBF (*i.e*. *RUNX1* and *CBFB*), a heterodimeric transcription factor complex required for normal hematopoiesis \[[@R1]\]. Importantly, experiences from murine models \[[@R2]\], as well as the existence of preleukemic cells harboring a CBF rearrangement in healthy individuals \[[@R3], [@R4]\], have demonstrated that CBF disruption is insufficient to induce leukemia. CBF-AML is therefore considered as a model of multistep pathogenesis. Evidences supporting this model have been generated by the high frequency of cooperative events at time of diagnosis. Notably, mutations in genes encoding tyrosine kinase pathways effectors (especially *KIT*, *FLT3* and *RAS* mutations) are found in up to 80% of CBF-AML patients \[[@R5]--[@R7]\]. Additional chromosomal aberrations are detected in approximately 70% of patients with t(8;21)-AML and 40% of patients with inv(16)-AML by conventional karyotype \[[@R5], [@R8]--[@R10]\]. These aberrations are nonrandom events and some of them are extremely rare in non-CBF-AML. In this context, the identification of recurrent events involved in CBF-AML pathophysiology and heterogeneity remains of great interest. We report here the SNP-array profiling of a large and well-annotated cohort of pediatric and adult patients with CBF-AML and the identification of new recurrent lesions in this particular subtype of leukemia.

RESULTS {#s2}
=======

CBF-AML genomes are characterized by a limited number of SNP-array-lesions {#s2_1}
--------------------------------------------------------------------------

SNP-array analysis of 116 t(8;21)-AML and 82 inv(16)-AML revealed a total of 319 lesions, including 277 copy-number abnormalities (CNAs; 187 losses and 90 gains; median size: 26.1 Mb \[range: 26 kb-155.1 Mb\]) and 42 CN-LOH ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Overall, 97 (84%) patients with t(8;21)-AML and 55 (64%) patients with inv(16)-AML had at least one genomic aberration (CNA and/or CN-LOH). There was no significant difference in the number of lesions between adult and pediatric patients ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}) arguing for similar diseases as previously described \[[@R6]\]. Recurrent focal lesions associated with t(8;21) and inv(16) breakpoints were common events, occurring in 27 (14%) CBF-AML cases especially in the inv(16) subtype (22% *vs.* 7%, p=0.005). Considering them as part of the primary event, t(8;21) or inv(16), breakpoint-associated lesions (accounting for 41 of the 319 identified lesions) were excluded for subsequent descriptions. Finally, CBF-AML genomes exhibited a mean of 1.40 SNP-array aberrations per case (range: 0-7)(Table [1](#T1){ref-type="table"}). CNAs were more numerous in t(8;21)-AML than in inv(16)-AML, mostly due to genomic deletions (0.98 *vs.* 0.44 losses/case respectively; p\<0.001). Neither the presence of SNP-array lesions nor the number of lesions was a predictor of outcome ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

###### Mean number of SNP-array lesions per CBF AML case according to genetic subtype

                                       CBF AML      t(8;21) AML   inv(16) AML   p-value   
  ------------------------------------ ------------ ------------- ------------- --------- ------
  Patients, n                          198          116           82                      
  Number of CNAs^†^, mean (range)      1.19 (0-6)   1.35 (0-5)    0.96 (0-6)    0.004     ^\*^
   Gains^†^, mean (range)              0.43 (0-4)   0.37 (0-4)    0.52 (0-3)    0.084     
   Losses^†^, mean (range)             0.76 (0-4)   0.98 (0-3)    0.44 (0-4)    \<0.001   ^\*^
  Number of CN-LOH^†^, mean (range)    0.21 (0-6)   0.17 (0-6)    0.27 (0-4)    0.372     
  Breakpoint lesions, mean (range)     0.21 (0-2)   0.09 (0-2)    0.38 (0-2)    0.002     ^\*^
  Total CNAs/CN-LOH^†^, mean (range)   1.40 (0-7)   1.53 (0-7)    1.23 (0-7)    0.020     ^\*^

CNA: copy number abnormality; CN-LOH: copy neutral-loss of heterozygosity.

^†^ excluding breakpoint-associated lesions.

SNP-array karyotyping in CBF-AML shows nonrandom copy number changes {#s2_2}
--------------------------------------------------------------------

Recurrent CNAs are listed in Table [2](#T2){ref-type="table"}. Considering lesions that are non-associated with breakpoints, a large proportion of detected CNAs were broad aberrations or involved whole chromosomes (Figure [1](#F1){ref-type="fig"}) \[[@R11]\]. Most of them appeared to be nonrandom events and are usually seen by conventional karyotype \[[@R1]\]. Among t(8;21)-AML patients, loss of a sex chromosome (LOS) was by far the most common event, occurring in 62 (53%) patients, followed by interstitial deletion of the long arm of chromosome 9 \[del(9q)\] in 15 (13%) patients (p\<0.001). Both aberrations were virtually absent among inv(16)-AML patients. All but one case with del(9q) shared a minimal deleted region (MRD) of 6.1Mb containing 19 genes ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) in which *TLE1* and *TLE4* have been the most studied \[[@R12], [@R13]\]. By contrast, +22 was restricted to inv(16)-AML and occurred in 11 (13%) patients. Trisomy 8 and interstitial deletion of the long arm of chromosome 7 \[del(7q)\] were found in both genetic subtypes. Trisomy 8 was observed in 8 (10%) cases with inv(16) and 6 (5%) cases with t(8;21). Gain of the long arm of chromosome 8 (+8q) was seen is 2 additional cases with inv(16) (2 other cases with t(8;21) had +8q related to the rarely described duplication of the derivate chromosome der(21) t(8;21) \[[@R14]\]; [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Del(7q) was found in 20 (10%) patients, including 10 (9%) cases with t(8;21) and 10 (12%) cases with inv(16). All cases with del(7q), whatever their genetic subtype t(8;21) or inv(16), shared a MDR of 4.2 Mb containing 71 genes in which the 2 epigenetics-related genes *EZH2* and *KMT2C* (*MLL3*) were the more relevant and have already been studied by others \[[@R15]--[@R17]\] ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). Overall, we did not find any association between these recurrent genetic aberrations and clinical outcome ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). Other broad recurrent aberrations included a previously undescribed deletion 2q which appeared to be restricted to patients with t(8;21)-AML (n=5) as well as gains 1q (n=2), 4q (n=3) and 13q (n=3). All patients with gain(13q) had also del(7q) in SNP-array while conventional karyotype showed additional material of unknown origin on the long arm of chromosome 7 \[add(7q)\]. Whole chromosome 13 painting performed in one of them by fluorescent *in situ* hybridization confirmed transfer of material from chromosome 13 to chromosome 7 leading to both gain(13) and del(7q) ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}).

###### Recurrent copy number abnormalities in CBF AML patients

  Recurrent SNP-array lesions         Start ^¥^          End ^¥^       Size       Gene count                                      CBF AML    inv(16)    t(8;21)    p-value   
  ----------------------------------- ------------------ ------------- ---------- ----------------------------------------------- ---------- ---------- ---------- --------- ------
  gain(1)(q42.13q44)                  227 833 996        249 224 684   21391 kb   197 genes                                       2 (1%)     0 (0%)     2 (2%)     0.512     
  del(2)(q33.2q35)                    204 563 014        220 260 561   15698 kb   127 genes                                       5 (3%)     0 (0%)     5 (4%)     0.078     
  del(3)(p13)                         71 194 153         71 523 438    329 kb     ***FOXP1***                                     4 (2%)     4 (5%)     0 (0%)     0.028     ^\*^
  gain(4)(q32.1q35.2)                 158 379 102        190 957 473   32578 kb   124 genes                                       3 (2%)     1 (1%)     2 (2%)     1.000     
  del(7)(q35q36.1)                    147 660 930        151 908 681   4248 kb    71 genes including ***EZH2*** and ***KMT2C***   20 (10%)   10 (12%)   10 (9%)    0.476     
  del(8)(q24.11)                      117 823 216        117 914 100   91 kb      ***RAD21****, RAD21-AS1, MIR3610*               2 (1%)     0 (0%)     2 (2%)     0.512     
  focal gain(8)(q24.21)^†^            130 586 319        130 697 500   111 kb     ***CCDC26***                                    9 (5%)     4 (5%)     5 (4%)     1.000     
  gain(8)(q24.11q24.3)^†^             118 660 515        140 821 810   22161 kb   92 genes including ***CCDC26*** and ***MYC***   2 (1%)     2 (2%)     0 (0%)     0.170     
  trisomy 8^†^                        whole chromosome   \-            \-         14 (7%)                                         8 (10%)    6 (5%)     0.264                
  del(9)(q21.2q21.33)                 80 806 493         86 951 615    6145 kb    19 genes including ***TLE1*** and ***TLE4***    14 (7%)    0 (0%)     14 (12%)   \<0.001   ^\*^
  trisomy 9                           whole chromosome   \-            \-         2 (1%)                                          2 (2%)     0 (0%)     0.170                
  del(11)(p13)                        31 972 741         32 633 735    661 kb     *RCN1,* ***WT1****, WT1-AS, EIF3M, CCDC73*      4 (2%)     2 (2%)     2 (2%)     1.000     
  gain(13)(q31.1q34)                  85 412 329         115 107 733   29695 kb   135 genes                                       3 (2%)     1 (1%)     2 (2%)     1.000     
  del(17)(q11.2)                      29 357 586         29 520 056    162 kb     *MIR4733,* ***NF1***                            2 (1%)     2 (2%)     0 (0%)     0.170     
  trisomy 21                          whole chromosome   \-            \-         3 (2%)                                          3 (4%)     0 (0%)     0.070                
  trisomy 22                          whole chromosome   \-            \-         11 (6%)                                         11 (13%)   0 (0%)     \<0.001    ^\*^      
  del(X)(q26.1)                       129 129 272        129 211 954   83 kb      ***BCORL1****, ELF4*                            2 (1%)     2 (2%)     0 (0%)     0.170     
  loss X or Y                                                                                                                     63 (32%)   1 (1%)     62 (53%)   \<0.001   ^\*^
   loss X^§^                          whole chromosome   \-            \-         22 (24%)                                        0 (0%)     22 (42%)   \<0.001    ^\*^      
   loss Y^§^                          whole chromosome   \-            \-         41 (39%)                                        1 (2%)     40 (63%)   \<0.001    ^\*^      
  **Breakpoint-associated lesions**                                                                                                                                          
  del(8)(q21.3)                       93 096 598         93 128 271    32 kb      ***RUNX1T1***                                   5 (3%)     0 (0%)     5 (4%)     0.078     
  del(16)(p13.11)                     15 828 494         16 056 322    228 kb     ***MYH11,*** *FOPNL, ABCC1*                     16 (8%)    16 (20%)   0 (0%)     \<0.001   ^\*^
  gain(16)(p13.11)                    15 725 039         15 814 747    90 kb      *KIAA0430, NDE1, MIR484,* ***MYH11***           1 (1%)     1 (1%)     0 (0%)     0.414     
  del(16)(q22.1)                      67 132 654         67 176 123    43 kb      ***CBFB****, C16orf70*                          13 (7%)    13 (16%)   0 (0%)     \<0.001   ^\*^
  gain(16)(q21q22.1)                  65 352 347         67 131 638    1779 kb    23 genes including ***CBFB***                   1 (1%)     1 (1%)     0 (0%)     0.414     
  del(21)(q22.12)                     36 183 871         36 210 100    26 kb      ***RUNX1***                                     3 (2%)     0 (0%)     3 (3%)     0.268     
  gain(21)(q22.12)                    36 355 481         36 423 085    68 kb      ***RUNX1,*** *RUNX1-IT1*                        2 (1%)     0 (0%)     2 (2%)     0.512     
  +der(21) t(8;21)(q22;q22)           whole chromosome   \-            *-*        2 (1%)                                          0 (0%)     2 (2%)     0.512                

\* p-value \< 0.05.

† Partial chromosomal lesions were considered separately from abnormalities involving the whole chromosome. Gains 8q related to der(21) t(8;21) duplication (n=2) were considered apart from other lesions.

¥ Chromosomal locations were obtained from the Human Feb. 2009 (GRCh37/hg19) assembly of the UCSC Genome Browser (<http://genome.ucsc.edu/>).

§ Proportions are given within the female population for loss of X and the male population for loss of Y.

![Karyograms of detected SNP-array lesions by genetic subtype\
Each vertical line represents 1 event in 1 patient. Gains are in red, losses in green and CN-LOH in blue. Part **(A)** shows cases with t(8;21)-AML and part **(B)** shows cases with inv(16)-AML. Schematic representations were obtained using the Genomic Recurrent Event ViEwer (GREVE) web tool (<http://www.well.ox.ac.uk/GREVE>) \[[@R11]\].](oncotarget-09-6478-g001){#F1}

SNP-array identifies recurrent target genes involved in CBF-AML pathogenesis {#s2_3}
----------------------------------------------------------------------------

One of the most common alterations was copy number gains at locus 8q24, which concerned 27 (13.5%) CBF-AML patients through several mechanisms ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}): 14 (7%) patients had +8, 4 (2%) patients had broad gains of the long arm of the chromosome 8 and the 9 (4.5%) remaining patients harbored focal gains that contained a single putative gene referred to as *CCDC26* which has been recently linked to myeloid leukemia cell growth \[[@R18]\]. *FOXP1* focal deletions were identified in 4 patients, all with inv(16)-AML. Interestingly, subsequent sequencing of all coding exons of *FOXP1* by high-throughput sequencing (HTS) in the whole cohort identified 2 other inv(16) patients with *FOXP1* truncating mutations (Figure [2](#F2){ref-type="fig"}). On the other hand, no *FOXP1* deletion or mutation was found in t(8;21) patients.

![*FOXP1* aberrations in inv(16) AML patients\
**(A)** Focal deletions targeting the *FOXP1* gene were detected in 4 patients harboring an inv(16). **(B)** Targeted sequencing of *FOXP1* revealed to other inv(16) patients with *FOXP1* truncating mutations.](oncotarget-09-6478-g002){#F2}

Other recurrent focal aberrations included deletions of *WT1* (n=4), *BCORL1* (n=2), the cohesin core component *RAD21* (n=2) and the RAS pathway modulator *NF1* (n=2) whose mutations are recurrent in CBF-AML \[[@R6], [@R7]\]. Additionally, some focal unique CNAs involved highly relevant genes such as deletions of the transcription factors *IKZF1* (n=1) and *ETV6* (n=1), gain of *MYB* (n=1), deletions of the cohesin regulator *PDS5A* (n=1) or the potential tumor suppressor *MGA* (n=1). A gain of *CNOT4*, which amplification is expected to enhance JAK/STAT signaling \[[@R19]\], was seen in one patient as the sole secondary abnormality.

ZBTB7A is a target of CN-LOH in t(8;21)-AML {#s2_4}
-------------------------------------------

The short arm of chromosome 19 was recurrently affected by CN-LOH in 3 patients with restriction to the t(8;21) subtype. The minimal affected region was about 6 Mb and contained 209 genes. Notably, this region was previously reported by Kühn et *al.* in 2 t(8;21)-AML patients with paired samples \[[@R17]\]. This region contained the *ZBTB7A* gene recently described as highly mutated in patients with t(8;21)-AML but not in patients with inv(16)-AML \[[@R20], [@R21]\]. In order to validate *ZBTB7A* as a target of CN-LOH in 19p, we performed HTS of all coding exons of *ZBTB7A* in the whole cohort. We identified 23 *ZBTB7A* mutations in 19 patients (4 patients had 2 mutations) restricted to the t(8;21) subgroup (16%; [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Three patients harbored the same frameshift mutation at alanine 175. All patients with 19p CN-LOH harbored concomitant *ZBTB7A* mutation validating *ZBTB7A* as the target of this aberration (Figure [3A](#F3){ref-type="fig"}). Missense mutations clustered in the N-terminal BTB domain while frameshift mutations occurred through the whole protein as previously described by others \[[@R20], [@R21]\] (Figure [3B](#F3){ref-type="fig"}). We did not identify any association or exclusion with other known mutations (Figure [3C](#F3){ref-type="fig"}). There was no difference in age, sex or white blood cell count according the *ZBTB7A* mutational status. Finally, there was no impact of *ZBTB7A* mutations on overall survival (OS) and relapse-free survival (RFS) in t(8;21)-AML patients ([Supplementary Figure 8](#SD1){ref-type="supplementary-material"}).

![*ZBTB7A* aberrations in AML patients with t(8;21)\
**(A)** Concomitant mutation and CN-LOH in 3 patients with t(8;21)-AML. **(B)** ZBTB7A protein (NP_056982.1) and identified mutations (red = truncating; green = missense). BTB: BR-C ttk and bab; NLS: nuclear localization sequence; Zf: zinc finger. **(C)** Genomic landscape of t(8;21)-AML including *ZBTB7A* mutations.](oncotarget-09-6478-g003){#F3}

CCDC26 disruption is likely to be associated with aberrant tyrosine kinase signaling in CBF-AML {#s2_5}
-----------------------------------------------------------------------------------------------

Nine (4.5%) patients harbored focal gains confined to the *CCDC26* locus (Figure [4](#F4){ref-type="fig"}). Interestingly, it has been recently suggested that *CCDC26* could control myeloid leukemia cell growth through regulation of *KIT* expression \[[@R18]\]. Considering that hyperactive *KIT* mutations are highly prevalent in CBF-AML (about 35% of cases)\[[@R6]\] and that *CCDC26* focal amplification (*CCDC26*^amp^) is found more frequently in CBF-AML than in non CBF-AML \[[@R22], [@R23]\], these findings could reveal a new lesion associated with aberrant tyrosine kinase pathway activation in CBF-AML patients. Importantly, all but one patient harboring *CCDC26*^amp^ were *KIT* wild-type. In order to explore this hypothesis, expressions of the *KIT* receptor and the phosphorylated downstream effector AKT (AKTp473) were estimated on diagnostic blast cells by flow cytometry in patients with *CCDC26*^amp^ (n=3). Results were compared with blast cells isolated from patient with normal *CCDC26* copy number (*CCDC26*^nor^) and *KIT* mutation (*KIT*^mut^; n=4), *FLT3*-ITD (n=2) or *KIT*/*FLT3* wild-type (*KIT*^wt^/*FLT3*^wt^; n=3). All patients were *NRAS* and *KRAS* wild-type (*RAS*^wt^). Overall, there was no correlation between *KIT* expression and *CCDC26* copy number or *KIT*/*FLT3* mutational status. Median expression of AKTp473 showed a trend of higher expression in *CCDC26*^amp^-cells (+24%) compared with *CCDC26*^nor^/KIT^wt^/FLT3^wt^/RAS^wt^-cells (Figure [5](#F5){ref-type="fig"}). Although we could not directly linked AKTp473 and *CCDC26*^amp^, these data suggest an underlying mechanism leading to the activation of tyrosine kinase pathway in cells harboring *CCDC26*^amp^. On the other hand, median expression of AKTp473 clearly increased in *CCDC26*^nor^/*KIT*^wt^/*FLT3*-ITD/RAS^wt^-cells (+107%) compared with *CCDC26*^nor^/KIT^wt^/FLT3^wt^/RAS^wt^-cells while it was not observed for *CCDC26*^nor^/KIT^mut^/FLT3^wt^/RAS^wt^-cells.

![Focal *CCDC26* amplifications\
Horizontal grey lines illustrate focal recurrent amplifications detected in 9 CBF AML genomes across the *CCDC26* locus. The area inside the dotted lines represents the minimal amplified region shared by all patients. Major variants of CCDC26 mRNA are shown in black below the figure. Exons are indicated by boxes. The long transcript consists of four exons (from e1 to e4) and the short transcripts comprise 3 or 4 exons (from 1a to e4, more or less exon 2a). The arrow shows the retrovirus insertion site defined by Yin et *al* \[[@R37]\].](oncotarget-09-6478-g004){#F4}

![AKTp473 expression in blasts from CBF-AML patients\
**(A)** AKTpS473 expression level in a patient with *CCDC26* focal amplification (*CCDC26*^amp^). **(B)** AKTpS473 mean fluorescent intensity ratios according to *CCDC26* focal amplification and *KIT/FTL3/RAS* mutational status. Ratios were calculated as (MFI of blast cells)/(MFI of isotype IgG control).](oncotarget-09-6478-g005){#F5}

DISCUSSION {#s3}
==========

SNP-array karyotyping of 198 patients with CBF-AML highlight great differences between t(8;21)-AML and inv(16)-AML as described in most recent studies focused on cooperating mutations \[[@R6], [@R7], [@R20], [@R21], [@R24]--[@R26]\]. Notably, these studies identified frequent mutations in genes encoding epigenetic regulators and cohesin complex in t(8;21)-AML while they were absent in inv(16)-AML \[[@R6], [@R7], [@R20], [@R21]\]. Overall, we found more CNAs in t(8;21)-AML than in inv(16)-AML, mostly due to genomic deletions. Excluding breakpoint-associated lesions, the most common CNAs included large chromosomal lesions usually seen by conventional cytogenetics including LOS, del(9q), del(7q) and +8 in t(8;21)-AML compared with +22, del(7q), +8, +21 and +9 in inv(16)-AML. While it is clear that these events are nonrandom and contribute to the pathogenesis of CBF-AML, there was no association between clinical outcome and the number of SNP-array lesions nor the presence of these specific aberrations. Remarkably, there was no significant difference in the number of lesions between adult and pediatric patients suggesting they reflect the same entity and could be studied together in further biological experiments.

Concerning recurrent broad deletions, SNP-array led us to identify MDRs on chromosome 9 (involving *TLE1* and *TLE4*) and chromosome 7 (containing *EZH2* and *KMT2C*). In previous experiments, Dayyani et *al* shown that haploinsufficiency of *TLE1* and *TLE4* could overcome the negative survival and anti-proliferative effects of *RUNX1-RUNXT1* on myeloid progenitors and promote leukemogenesis \[[@R13]\]. Using SNP-array profiling, Kühn et *al* previously identified a MDR on 7q containing only 4 genes including *KMT2C* \[[@R17]\]. By sequence analysis of 46 CBF-AML without *KMT2C* deletion, they identified a single somatic heterozygous frameshift mutation in this gene. More recently, it was shown that *KMT2C* act as a tumor suppressor gene in AML \[[@R16]\]. Together, these data suggest that *KMT2C* haploinsufficiency is likely to be a cooperating event in CBF-AML pathogenesis. While the MDR defined by Kühn et *al* did not contain *EZH2*, by contrast with the present study, the high frequency of polycomb mutations *(ASXL1, ASXL2* and *EZH2)* in t(8;21)-AML suggest that *EZH2* haploinsufficiency could be of interested, at least in t(8;21)-AML patients \[[@R6], [@R27]\].

Although the number of CNAs was low, our analysis identified recurrent deletions and subsequent mutations in known and potentially new cancer genes. These included deletions in *WT1*, *BCORL1*, *RAD21*, *EZH2* or *NF1* whose mutations have been recurrently found in CBF-AML patients \[[@R6], [@R7], [@R20]\]. Interestingly, we identified *FOXP1* aberrations (deletions or truncated mutations) in 7% of patients with inv(16)-AML, arguing for a pathogenic role in this particular subtype. *FOXP1* (*forkhead box P1*) encodes one of the 4 members of the FOXP subfamily of forkhead transcription factors, known to be involved in human malignancies, cell survival and differentiation \[[@R28]\]. *FOXP1* has been described as a target of chromosomal translocations and amplifications in B-cell lymphomas and prostate cancer \[[@R28]\]. By contrast, *FOXP1* losses have been described in clear cell-type kidney cancer but also rarely in myeloproliferative neoplasms \[[@R29]\] and AML with normal \[[@R30]\] or complex karyotype \[[@R31]\]. *FOXP1* has been shown to function as a transcriptional repressor in monocytic differentiation \[[@R32]\]. Thus, it is likely that *FOXP1* loss-of-function could contribute to leukemogenesis especially in inv(16)-AML which is most often diagnosed as AML with a monocytic compartment \[[@R1]\].

Three patients with t(8;21)-AML had CN-LOH of 19p leading to homozygous *ZBTB7A* mutation. *ZBTB7A* (also known as *LRF* or *Pokemon*) encodes a transcription factor of the POK (*poxvirus and zinc finger and Krüppel*)/ZBTB (*zinc finger and broad complex, tramtrack, and bric-a-brac*) family involved in the hematopoietic development and the negative regulation of glycolysis \[[@R21]\]. Sequence analysis of *ZBTB7A* in the whole cohort identified mutations in 16% of t(8;21)-AML while no mutation was found in inv(16)-AML. Our results are in line with other studies previously reporting *ZBTB7A* mutations in 10% to 23% of t(8;21)-AML \[[@R7], [@R20], [@R21]\]. Somatic *ZBTB7A* mutations are also reported at low frequencies in various solid malignancies \[[@R33]\]. Missense mutations identified in our analysis clustered in the BTB domain which mediates the homodimerization and/or heterodimerization with other proteins \[[@R33]\]. Truncated mutations were distributed through the whole gene leading to the loss of the zinc-finger domain involved in DNA binding and/or nuclear localization signal. Previous experiments from Hartmann et *al* suggest that *ZBTB7A* act as a tumor suppressor in t(8;21)-AML \[[@R20]\]. Overexpression of *ZBTB7A* in Kasumi-1 cells (cell line harboring a t(8;21) rearrangement) leads to reduced proliferation while its haploinsufficiency should result in the induction of glycolysis promoting tumor progression \[[@R20], [@R33]\].

Finally, we identified *CCDC26* (*coiled-coil domain containing* 26) focal amplifications in 4.5% of the total cohort, consistent with previous SNP-array investigations showing such lesions in 4.7% of CBF-AML genomes \[[@R17], [@R22]\]. The nature of *CCDC26* remains ambiguous but it is more plausible that the *CCDC26* locus encodes a long non-coding-RNA \[[@R34]\] involved in tumors, including low-grade gliomas \[[@R35]\] and pancreatic cancer \[[@R36]\]. This locus, also known as *RAM* (*retinoic acid modulator*), was initially reported as required for retinoic acid (RA)-induced myeloid differentiation. Retroviral DNA integration into this locus has been shown to generated RA-resistant cells \[[@R37]\]. Interestingly, Hirano et *al* showed that *CCDC26*-knockdown resulted in *KIT* up-regulation and enhanced survival in myeloid leukemia cell lines. First of all, these results appeared conflicting with our data showing *CCDC26* amplification in CBF-AML. However, this paradox could be explicable by the fact that *CCDC26* amplification does not extend to the whole gene. Partial amplification restricted to exons 1 and 1a could result in *CCDC26* disruption leading to an abnormal mRNA structure without any activity or able to interfere with the remaining intact gene \[[@R38]\]. Thus, considering the high frequency class I mutations (especially in *KIT*, *FLT3* and *RAS* genes) in CBF-AML \[[@R6]\], it is likely that *CCDC26* disruption could highlight a new class I aberration leading to increased cell survival and proliferation in leukemia. In order to explore this hypothesis, we studied phosphoAKT expression by flow cytometry in CBF-AML cells harboring *CCDC26* focal amplification. Although we were able to study only 3 patients with this lesion, blast cells from patients with *CCDC26* disruption showed a subtle increased expression of phosphoAKT compared with blast cells from patients with normal *CCDC26* copy number and no class I mutation (*KIT*, *FLT3* and *RAS* wild-type). However, this was not observed blast cells from 4 *KIT*-mutated patients suggesting other activated pathways associated with *KIT* mutations. By contrast phosphoAKT expression were clearly increased in blast cells from 2 patients with *FLT3-ITD*. Unfortunately, we were not able to study other cytoplasmic effectors such as ERK, SRC or STAT proteins that could be deregulated in leukemia. Also, because we studied a very small number of patients, we were not able to give strong conclusions but our data suggest a mechanism leading to tyrosine kinase signaling in cells with *CCDC26* disruption. Of course, further studies are needed to directly link *CCDC26* disruption and aberrant tyrosine kinase signaling in CBF-AML.

In conclusion, we defined the landscape of SNP-array lesions in a cohort of 198 adult and pediatric CBF-AML at time of diagnosis. As no cell culture is required, we described the frequency of known cytogenetic abnormalities with an unbiased approach and found no association with clinical outcome. Although, the number of SNP-array lesions appeared very low in CBF-AML, when combining with sequence analyses, we were able to identify recurrent involvement of known and potentially new cancer genes including *FOXP1* loss-of-function in inv(16)-AML, *ZBTB7A* homozygous mutations through CN-LOH in t(8;21)-AML and *CCDC26* disruption in both genetic subgroups of CBF-AML. Because of the low frequency of recurrent events, further studies focused on specific genetic subgroups of AML are needed to specify the incidence and the role of these aberrations in leukemogenesis.

MATERIALS AND METHODS {#s4}
=====================

Patients and samples {#s4_1}
--------------------

This study focused on diagnostic bone marrow (BM) samples from 198 CBF-AML patients including 116 AML with t(8;21) and 82 AML with inv(16). The cohort included 125 adults (aged from 18 to 60 years) and 73 children (aged from 1 to 17 years) enrolled in the French trials CBF2006 ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT00428558)\[[@R5]\] and ELAM02 ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT00149162) respectively. Median age was 30 years (range: 1-60). Patient's characteristics are summarized in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}. Studies were approved by the Ethics Committee of Nîmes University Hospital and by the Institutional Review Board of the French Regulatory Agency and were conducted in accordance with the Declaration of Helsinki. Details about treatment regimens are provided in [Supplementary Figure 9](#SD1){ref-type="supplementary-material"} and [Supplementary Figure 10](#SD1){ref-type="supplementary-material"}.

SNP-array karyotyping {#s4_2}
---------------------

DNA was extracted from diagnostic cell pellets using the QIAamp Tissue Kit (Qiagen) according to the manufacturer's instructions. Patient's genomic DNA was processed and hybridized to Cytoscan HD array (Affymetrix) according to the manufacturer's protocol. Data were analyzed using the Chromosome Analysis Suite (ChAS) software (Affymetrix). In a first step, only copy number variants with a size over 20 kb including at least 20 consecutive markers as well as CN-LOH over 3 Mb were considered for this analysis. In a second step, we adopted a stringent and conservative algorithm in order to distinguish somatic from constitutional SNP-array lesions. Variations were excluded as known copy number variants if there was more than 50% overlap with variants from the public Database of Genomic Variants. Based on previous studies \[[@R39]--[@R41]\], only interstitial CN-LOH over 10 Mb and CN-LOH extending to telomeres were considered to be acquired abnormalities. Remaining CN-LOH were considered as possibly constitutional and then rejected for subsequent analyses. Finally, all CNAs and CN-LOH fulfilling the above criteria were validated by visual inspection and annotated for size, position and location of genes based on the human genome version 19 (hg19) of the UCSC Genome Browser.

Mutational analysis {#s4_3}
-------------------

Considering data from SNP-array karyotyping, target sequencing was performed for all coding exons of *FOXP1* (NM_001244810) and *ZBTB7A* (NM_015898). Libraries were prepared using the Ampliseq system according to the manufacturer's instruction and run on Personal Genome Machine (PGM, Life Technologies). Raw HTS data from PGM sequencing were processed by Torrent Browser (Life Technologies) and SeqNext (JSI Medical System). The depth of coverage was more than 2000X for both genes. Variants were confirmed by direct Sanger Sequencing as previously described \[[@R27]\]. Frameshift and nonsense variants were always considered as relevant mutations. Single nucleotide variants were retained in the absence of description into public databases of human polymorphisms and effects on protein function were predicted with SIFT and Polyphen-2.

Multiparameter flow cytometry {#s4_4}
-----------------------------

Diagnostic blast cells were obtained from thawed cryopreserved BM samples after red blood cell lysis. Fixation, permeabilization and staining (with both intracellular and cell surface markers) were performed using the PerFix-no centrifuge assay kit (Beckman Coulter) according to the manufacturer's instructions. The antibody panel contained: anti-AKTpS473-Vio515 (clone: REA359, Miltenyi Biotec), anti-CD33-PC5.5 (clone D3HL60.251, Beckman Coulter), anti-CD34-PC7 (clone 581, Beckman Coulter), anti-CD117/KIT-APC (clone 104D2D1, Beckman Coulter), anti-CD3-AA750 (clone UCHT1, Beckman Coulter), anti-CD4-PB (clone 13B8.2, Beckman Coulter) and anti-CD45-KO (clone J33, Beckman Coulter). Blast cells were gated as CD45^dim^, SSC^low^, CD33+, excluding lymphocytes (CD45^bright^, SSC^low^, CD33−), monocytes (CD45int/bright, SSC^int^, CD33^bright^) and mature myelomonocytic cells (CD45^int^, SSC^high^, CD33^dim/neg^). Isotype control (clone REA293, Miltenyi Biotec) was used to better define the threshold of AKTpS473-positive cells. AKTpS473 expression levels were calculated as \[mean fluorescent intensity (MFI) of blast cells/MFI of isotype IgG control\]. Measurements were performed on a Navios flow cytometer and analyzed with Kaluza software (Beckman-Coulter).

Statistical methods {#s4_5}
-------------------

Failure time data were analyzed and compared after censoring at transplant for patients who received allogeneic stem cell transplantation in first complete remission (CR). RFS and OS were estimated by the Kaplan-Meier method. RFS was estimated taking into account death in first CR for competing risk. Comparisons between patient subgroups were performed by the Mann-Whitney test for continuous variables and by Fisher's exact test for categorical variables. All statistical tests were performed with the SPSS Statistics software (IBM).

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
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AML

:   acute myeloid leukemia

BM

:   bone marrow

CBF

:   core binding factor

CNAs

:   copy-number abnormalities

CN-LOH

:   copy-neutral losses of heterozygosity

CR

:   complete remission

HTS

:   high-throughput sequencing

LOS

:   loss of a sex chromosome

MFI

:   mean fluorescent intensity

OS

:   overall survival

RA

:   retinoic acid

RFS

:   relapse-free survival

SNP

:   single nucleotide polymorphism
